This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedman, A. Articles by Wang, J. Search for Related Content PubMed PubMed Citation Articles by Friedman, A. Articles by Wang, J.

Glioma Virotherapy: Effects of Innate Immune Suppression and Increased Viral Replication Capacity

¹ Mathematical Biosciences Institute; ² Dardinger Center for Neuro-oncology and Neurosciences, Department of Neurological Surgery; ³ Department of Mathematics, The Ohio State University, Columbus, Ohio and ⁴ Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Jianjun Paul Tian, Mathematical Biosciences Institute, The Ohio State University, 18th Avenue, Columbus, OH 43210. Phone: 614-688-3443; E-mail: tianjj{at}mbi.ohio-state.edu.

Oncolytic viruses are genetically altered replication-competent viruses that infect, and reproduce in, cancer cells but do not harm normal cells. On lysis of the infected cells, the newly formed viruses burst out and infect other tumor cells. Experiments with injecting mutant herpes simplex virus 1 (hrR3) into glioma implanted in brains of rats show lack of efficacy in eradicating the cancer. This failure is attributed to interference by the immune system. Initial pretreatment with immunosuppressive agent cyclophosphamide reduces the percentage of immune cells. We introduce a mathematical model and use it to determine how different protocols of cyclophosphamide treatment and how increased burst size of the mutated virus will affect the growth of the cancer. One of our conclusions is that the diameter of the cancer will decrease from 4 mm to eventually 1 mm if the burst size of the virus is triple that which is currently available. The effect of repeated cyclophosphamide treatment is to maintain a low density of uninfected cells in the tumor, thus reducing the probability of migration of tumor cells to other locations in the brain. (Cancer Res 2006; 66(4): 2314-9)

This article has been cited by other articles:

				D. Dhar, J. F. Spencer, K. Toth, and W. S. M. Wold Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters J. Virol., March 1, 2009; 83(5): 2130 - 2139. [Abstract] [Full Text] [PDF]

				T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 Clin. Cancer Res., January 15, 2009; 15(2): 561 - 569. [Abstract] [Full Text] [PDF]

				J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269. [Abstract] [Full Text] [PDF]

				G. Fulci, N. Dmitrieva, D. Gianni, E. J. Fontana, X. Pan, Y. Lu, C. S. Kaufman, B. Kaur, S. E. Lawler, R. J. Lee, et al. Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses Cancer Res., October 1, 2007; 67(19): 9398 - 9406. [Abstract] [Full Text] [PDF]

				G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S. S. Rhee, J. Yu, B. Kaur, D. N. Louis, R. Weissleder, M. A. Caligiuri, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses PNAS, August 22, 2006; 103(34): 12873 - 12878. [Abstract] [Full Text] [PDF]